Literature DB >> 29111602

Scedosporium apiospermum infection of the urinary system with a review of treatment options and cases in the literature.

Esther Benamu1, Alexander Tin-Han Yu1, Lijia Xie2, Sebastian Fernandez-Pol3, Anne Y Liu1, Dora Y Ho1.   

Abstract

Infection with Scedosporium species is associated with a significant morbidity and mortality and is becoming increasingly common, especially in immunocompromised patients. We describe the presentation and successful management of an immunocompromised patient with Scedosporium apiospermum infection of the upper urinary tract system, a rare disease manifestation. The current literature on urinary tract scedosporiosis is further reviewed with emphasis on treatment options and limitations of current antifungal therapy.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990Scedosporiumzzm321990; bone marrow transplant; genitourinary; kidney; opportunistic infection; transplantation; urinary

Mesh:

Substances:

Year:  2017        PMID: 29111602      PMCID: PMC5871223          DOI: 10.1111/tid.12804

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  22 in total

1.  Candida urinary tract infections--treatment.

Authors:  John F Fisher; Jack D Sobel; Carol A Kauffman; Cheryl A Newman
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

2.  Utility of DNA sequencing for direct identification of invasive fungi from fresh and formalin-fixed specimens.

Authors:  Pablo A Moncada; Indre Budvytiene; Dora Y Ho; Stanley C Deresinski; Jose G Montoya; Niaz Banaei
Journal:  Am J Clin Pathol       Date:  2013-08       Impact factor: 2.493

3.  Clinical and morphologic findings in disseminated Scedosporium apiospermum infections in immunocompromised patients.

Authors:  Molly M Campa-Thompson; James A West; Joseph M Guileyardo; Cedric W Spak; Louis M Sloan; Stacy G Beal
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-07

Review 4.  Successful treatment of disseminated scedosporium infection in 2 lung transplant recipients: review of the literature and recommendations for management.

Authors:  Michael Musk; Daniel Chambers; Weng Chin; Ronan Murray; Eli Gabbay
Journal:  J Heart Lung Transplant       Date:  2006-10       Impact factor: 10.247

5.  Disseminated mycosis due to Scedosporium prolificans in an AIDS patient with Burkitt lymphoma.

Authors:  P Nenoff; U Gütz; K Tintelnot; A Bosse-Henck; M Mierzwa; J Hofmann; L C Horn; U F Haustein
Journal:  Mycoses       Date:  1996 Nov-Dec       Impact factor: 4.377

Review 6.  Scedosporium apiospermum (Pseudoallescheria boydii) infection in lung transplant recipients.

Authors:  Hina Sahi; Robin K Avery; Omar A Minai; Geraldine Hall; Atul C Mehta; Paola Raina; Marie Budev
Journal:  J Heart Lung Transplant       Date:  2007-03-02       Impact factor: 10.247

7.  Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model.

Authors:  M A Ghannoum; I Okogbule-Wonodi; N Bhat; H Sanati
Journal:  J Chemother       Date:  1999-02       Impact factor: 1.714

8.  In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates.

Authors:  Joseph Meletiadis; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.

Authors:  Bharat D Damle; James A Dowell; Robert L Walsky; Gregory L Weber; Martin Stogniew; Philip B Inskeep
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

10.  Combination Antifungal Therapy in the Treatment of Scedosporium apiospermum Central Nervous System Infections.

Authors:  Andrés F Henao-Martínez; José R Castillo-Mancilla; Michelle A Barron; Aran Cunningham Nichol
Journal:  Case Rep Infect Dis       Date:  2013-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.